{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:46:17Z","timestamp":1792320377755,"version":"4.4.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T00:00:00Z","timestamp":1451260800000},"content-version":"vor","delay-in-days":5474,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2001]]},"DOI":"10.1046\/j.1469-0691.2001.00060.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T07:25:53Z","timestamp":1047367553000},"page":"66-74","source":"Crossref","is-referenced-by-count":41,"special_numbering":"S4","title":["The oxazolidinones as a new family of antimicrobial agent"],"prefix":"10.1016","volume":"7","author":[{"given":"A.","family":"Marchese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.C.","family":"Schito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1046\/j.1469-0691.2001.00060.x_bib1","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1128\/AAC.31.11.1791","article-title":"Oxazolidinones, a new class of synthetic antibacterial agents: in vitro activities of DuP 105 and DuP 721","volume":"31","author":"Slee","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib2","first-page":"435","article-title":"Oxazolidinones: a new class of antimicrobials","volume":"16","author":"Ford","year":"1999","journal-title":"Infect Med"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib3","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00003495-200059040-00007","article-title":"Linezolid","volume":"59","author":"Clemett","year":"2000","journal-title":"Drugs"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib4","author":"Mirasol"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib5","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1128\/AAC.41.10.2127","article-title":"The oxazolidinone eperezolid binds to the 50S ribosomial subunit and competes with binding of chloramphenicol and lincomycin","volume":"41","author":"Lin","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib6","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1128\/AAC.41.10.2132","article-title":"Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions","volume":"41","author":"Shinabarger","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib7","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Mechanisms of resistance to oxazolidinones [abstract 1134]","author":"Shinabarger","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1006\/jmbi.1999.3247","article-title":"Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the rybosomal peptidyl transferase center","volume":"294","author":"Kloss","year":"1999","journal-title":"J Mol Biol"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/45.6.797","article-title":"Activity of linezolid against G+ cocci possessing genes conferring resistance to protein synthesis inhibitors","volume":"45","author":"Fines","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1128\/AAC.40.4.839","article-title":"In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents","volume":"40","author":"Zurenko","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib11","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/AAC.40.3.799","article-title":"In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis","volume":"40","author":"Kaatz","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib12","series-title":"Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA","article-title":"Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid [abstract 848]","author":"Zurenko","year":"1999"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib13","series-title":"Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New OrleanS","article-title":"Mutation of the Acr AB antibiotic efflux pump in Escherichia coli confers susceptibility to oxazolidinone antibiotics [abstract 848]","author":"Buysse","year":"1996"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib14","series-title":"Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Linezolid safety, tolerance, and pharmacokinetics following oral dosing twice daily for 14.5 days [abstract A115]","author":"Stalker","year":"1997"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib15","series-title":"Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Linezolid safety, tolerance, and pharmacokinetics after intravenous dosing twice daily for 7.5 days [abstract A116]","author":"Stalker","year":"1997"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib16","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1128\/JCM.35.12.3198-3202.1997","article-title":"Disk diffusion test interpretative criteria and quality control recommendations for testing linezolid (U100766) and eperezolid (U-100592) with commercially prepared reagents","volume":"35","author":"Biedenbach","year":"1997","journal-title":"J Clin Microbiol"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib17","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jac\/42.6.721","article-title":"The in-vitro activity of linezolid (U-100766) and tentative breakpoints","volume":"42","author":"Wise","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/AAC.41.2.465","article-title":"In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase negative Staphylococcus species","volume":"41","author":"Jorgensen","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib19","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/AAC.40.3.799","article-title":"In vitro activity of oxazolidinone compounds U100592 and U100766 versus. Staphylococcus aureus and Staphylococcus epidermidiS","volume":"40","author":"Kaatz","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0732-8893(97)00210-1","article-title":"Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci","volume":"30","author":"Bostic","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0732-8893(97)00071-0","article-title":"Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid","volume":"28","author":"Schaadt","year":"1997","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s100960050265","article-title":"Susceptibility testing of linezolid by two standard methids","volume":"18","author":"Hamilton-Miller","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib23","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/jac\/46.6.931","article-title":"Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid","volume":"46","author":"Henwood","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib24","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Activity of linezolid against medically important Gram-positive bacteria from 1997 to 1999 [abstract 2299]","author":"Borek","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib25","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"In vitro activity of linezolid against Gram-positive infection in continuous ambulatory peritoneal dialysis patients [abstract 2300]","author":"Bowker","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib26","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1128\/AAC.43.8.2059","article-title":"In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci","volume":"43","author":"Noskin","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib27","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Comparative activity of linezolid against Staphylococci and Enterococci isolated in Italy [abstract 2302]","author":"Mezzatesta","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib28","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Comparative in vitro activities of linezolid and other new agents against methicillin-resitant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative Staphylococci [abstract 2994]","author":"Betriu","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib29","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1128\/AAC.40.3.720","article-title":"In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones","volume":"40","author":"Jones","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib30","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1128\/AAC.40.7.1745","article-title":"In vitro activities of new oxazolidinone antimicrobial agents against enterococci","volume":"40","author":"Eliopoulos","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib31","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1128\/AAC.44.7.1838-1841.2000","article-title":"Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and \u2013resistant streptococci","volume":"44","author":"Betriu","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1128\/AAC.40.2.481","article-title":"Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci","volume":"40","author":"Spangler","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jac\/42.6.721","volume":"42","author":"Rybak","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/47.1.77","article-title":"In vitro activity of linerzolid against multiply resistant Gram-positive clinical isolates","volume":"47","author":"Cercenado","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib35","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/jac\/43.4.569","article-title":"Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinpristin\/dalfopristin and linezolid against staphylococci","volume":"43","author":"Von Eiff","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib36","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/JCM.36.4.1020-1027.1998","article-title":"Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides","volume":"36","author":"Tenover","year":"1998","journal-title":"J Clin Microbiol"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib37","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1128\/JCM.38.2.866-869.2000","article-title":"Heterogeneous vancomycin resistance in methicillin-resistant S. aureus strains isolated in a large Italian Hospital","volume":"38","author":"Marchese","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib38","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.44.4.1062-1066.2000","article-title":"In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and- resistant strains","volume":"44","author":"Rybak","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib39","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1128\/AAC.40.4.1039","article-title":"In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae","volume":"40","author":"Mason","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib40","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Linezoli is active against Streptococcus pneumoniae resistant to other protein synthesis inhibiting antibiotics [abstract 2301]","author":"Zhanel","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib41","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1086\/517221","article-title":"Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin","volume":"28","author":"Noskin","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib42","unstructured":"Brown BA, Ward SC, Mann L et al In vitro activity of linezolid against multiple species of nocardia: a new drug of choice for a difficult disease? In: Proceedings of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, Seville, Spain. New York: Marcel Dekker."},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib43","series-title":"Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA","article-title":"Minimum inhibitory concentration determinations for oxazolidinone antimicrobial agents and comparator agents against strains of Rhodococcus equi [E-129 abstract]","author":"Salmon","year":"1998"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib44","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1128\/AAC.43.6.1469","article-title":"Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans","volume":"43","author":"Goldstein","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1469-0691.1999.tb00099.x","article-title":"In vitro activity of linezolid and eperezolid against anaerobic bacteria","volume":"5","author":"Edlund","year":"1999","journal-title":"Clin Microbiol Infect"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib46","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1128\/AAC.42.6.1520","article-title":"Susceptibilities of Legionella spp. to newer antimicrobials in vitro","volume":"42","author":"Sch\u00fclin","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib47","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1179\/joc.1999.11.3.220","article-title":"In vitrosusceptibilities of Bordetella pertussis and Bordetella parapertussis to the novel oxazolidinones eperezolid (PNU-100592) and linezolid (PNU-100766)","volume":"11","author":"Hoppe","year":"1999","journal-title":"J Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib48","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1086\/520309","article-title":"In vitro antibiotic synergy against Flavobacterium meningosepticum: implications for therapeutic options","volume":"26","author":"Di Pentima","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib49","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"In vitro activity of linezolid, anew oxazolidinone, against 127 anaerobes isolated from abdominal specimens and against 102 isolates (96 anaerobes) isolated from pulmunary specimens [abstract 2304]","author":"Wexler","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib50","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1128\/AAC.44.7.1977-1979.2000","article-title":"In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin and metronidazole against Helicobacter pylori","volume":"44","author":"Hirschl","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib51","series-title":"Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA","article-title":"Expression of virulence factors by Gram-positive cocci exposed to sub-MIC levels of linezolid [abstract 1537]","author":"Gemell","year":"1999"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib52","series-title":"Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA","article-title":"In vitro activity of linezolid combined with other antibacterial agents [abstract 1252]","author":"Sweeny","year":"1999"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib53","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"In vitro activity of linezolid combined with numerous antibacterial agents [abstract 2295]","author":"Sweeny","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib54","series-title":"Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA","article-title":"Pharmacodynamic activity of a new oxazolidinone, Linezolid, in an animal infection model [abstract A9]","author":"Andes","year":"1998"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib55","series-title":"Proceedings of the 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA","article-title":"Linezolid (L.) Vs Methicillin-Resistant Staphylococcus aureus in experimental rat endocarditis","author":"Gehman","year":"1999"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib56","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Methicillin-resistant Staphylococcus aureus (MRSA) rabbit endocarditis experimental model (REM): in vivo comparative activity between linezolid (L) vs vancomycin (V) [abstract 671]","author":"Jacqueline","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib57","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1128\/AAC.45.2.621-623.2001","article-title":"Linezolid therapy of vancomycin-resistant Enterococcus faecium experimantal endocarditis","volume":"45","author":"Patel","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib58","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jac\/46.6.981","article-title":"Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model","volume":"46","author":"Cottagnoud","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib59","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1128\/AAC.40.6.1508","article-title":"In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections","volume":"40","author":"Ford","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib60","series-title":"Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA","article-title":"Treatment of methicillin-sensitive Staphylococcus aureus experimental osteomyelitis with linezolid of cefazolin [abstract 1767]","author":"Piper","year":"1999"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib61","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.44.3.654-657.2000","article-title":"Efficacy of linezolid in experimental otitis media","volume":"44","author":"Pelton","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib62","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1128\/AAC.43.5.1189","article-title":"Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model","volume":"43","author":"Cynamon","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib63","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1128\/AAC.43.12.2873","article-title":"Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium","volume":"43","author":"Schulin","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 4","key":"10.1046\/j.1469-0691.2001.00060.x_bib64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1469-0691.2001.00061.x","article-title":"Linezolid. Pharmacokinetic characteristics and clinical studies","volume":"7","author":"Bouza","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib65","series-title":"Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA","article-title":"Metabolism and excretion of the oxazolidinone antibiotic linezolid (PNU 100766) following oral administration of [14C]PNU 100766 to healthy human volunteers [abstract A53]","author":"Feenstra","year":"1998"},{"issue":"Suppl. 1","key":"10.1046\/j.1469-0691.2001.00060.x_bib66","first-page":"54","article-title":"Assessment of absolute bioavailability and evaluation of the effect of food on oral bioavailability of linezolid","volume":"16","author":"Welshman","year":"1998","journal-title":"Antiinfect Drugs Chemother"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib67","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Intrapulmonary pharmacokinetics of linezolid. [abstract 659]","author":"Conte","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib68","series-title":"Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA","article-title":"In vitro metabolism of linezolid (PNU-100766): lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU-142586 [abstract 11]","author":"Wienkers","year":"1999"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib69","series-title":"Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA","article-title":"Safety and tolerance of linezolid in phase II trials [abstract 1763]","author":"Wilks","year":"1999"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib70","unstructured":"Jungbluth GL, Laser-Sisson T, Hopkins NK, Knechtel TJ, Burton NK, Donaldson KM. Linezolid and gentamicin or aztreonam: a pharmacokinatic evaluation of intravenous coadministration in healthy volunteers [abstract]. In: Program and Abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA. Alexandria, VA: Infectious Diseases Society of America."},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib71","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/00912709922011962","article-title":"A pharmacokinetic evaluation of concomitatnt administration of linezolid and aztreonam","volume":"39","author":"Sisson","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib72","series-title":"Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA","article-title":"Effect of age and gender on the single-dose pharmacokinetics of linezolid [abstract 1194]","author":"Lasher Sisson","year":"1999"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib73","first-page":"1061","article-title":"Pharmacokinetics of linezolid in paediatrie patients","volume":"27","author":"Stalker","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib74","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1097\/00006454-200012000-00012","article-title":"Single dose pharmacokinetics of linezolid in infants and children","volume":"19","author":"Kearns","year":"2000","journal-title":"Ped Infect Dis J"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib75","first-page":"276","article-title":"Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis","volume":"46","author":"Brier","year":"1998","journal-title":"J Invest Med"},{"issue":"Suppl. A","key":"10.1046\/j.1469-0691.2001.00060.x_bib76","first-page":"55","article-title":"Pharmacokinetics of linezolid in patients with liver disease","volume":"44","author":"Hendershot","year":"1999","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 2","key":"10.1046\/j.1469-0691.2001.00060.x_bib77","first-page":"A 844","article-title":"Efficacy of linezolid in community-acquired S. pneumoniae pneumonia","volume":"159","author":"Canimarata","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib78","first-page":"23","article-title":"First resistance to linezolid reported","volume":"2478","author":"Anonymous","year":"1999","journal-title":"Scripmag"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib79","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/318486","article-title":"Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 3","key":"10.1046\/j.1469-0691.2001.00060.x_bib80","first-page":"133","article-title":"Efficacy of linezolid in skin and soft tissue infections","volume":"5","author":"Cammarata","year":"1999","journal-title":"Clin Microbiol Infect"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib81","series-title":"Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA","article-title":"Outcomes with linezolid from an ongoing compassionate use (CU) trial of patients (pts) with significant, resistant Gram-positive infections [abstract 1098]","author":"Birmingham","year":"1999"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib82","series-title":"Proceedings of the 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA","article-title":"Results of treating bacteraemic patients with Linezolid in a compassionate use trial for resistant, Gram-positive infections [abstract A9]","author":"MC","year":"1999"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib83","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1086\/313897","article-title":"Successful treatment of vertebral osteomyelytis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylocccus aureus and vancomycin-resistant Enteroccus bacteremia","volume":"31","author":"Melzer","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib84","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1086\/313669","article-title":"Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin\/dalfopristin)","volume":"30","author":"McNeil","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib85","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Results of treating patients with significant, resistant, Gram positive, intra-abdominal infections with linezolid [abstract 2237]","author":"Root","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib86","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Results of treating infective endocarditis with linezolid [abstract 2239]","author":"Dresser","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib87","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1086\/313597","article-title":"Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections","volume":"30","author":"Chien","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib88","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Outcomes of linezolid in patients with malignancies and significant Gram positive infections. [abstract 2238]","author":"Birmingham","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib89","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Safety and tolerance of linezolid: adverse events reported in phase III trials [abstract 2263]","author":"Bruss","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib90","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Incidence of Clostridium difficile-related complications during clinical trials of linezolid on oxazolidinone [abstract 947]","author":"Cammarata","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib91","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Oxazolidinones. linezolid and beyond [abstract 637]","author":"Zurenko","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib92","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Synthesis and antibacterial activity of 2-aminomethyl-1, 3, 4-thiadiazole phenyl oxazolidinone thioamides [abstract 1829]","author":"Thomasco","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib93","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Combinatorial lead development of oxazolidinones: synthesis and in vitro activity of novel 3\u2032-fluoro-4\u2032thioether phenyloxazolidinones [abstract 1831]","author":"Luehr","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib94","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Combinatorial lead development of oxazolidinones: Synthesis and antimicrobial activity of 4\u2032-amido-3\u2032fluorophenyloxazolidinones [abstract 1832]","author":"Gordeev","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib95","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Combinatorial lead development of oxazolidinones: Synthesis and in vitro activity of novel 4\u2032-acylamino-3\u2032fluorophenyloxazolidinones [abstract 1833]","author":"Gordeev","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00060.x_bib96","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON","article-title":"Combinatorial lead development of oxazolidinones: novel tetrahydro-4 (2H)-thiopyran phenyloxazolidinones sulfoxides and sulfones [abstract 1834]","author":"Gordeev","year":"2000"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15301178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15301178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T22:14:16Z","timestamp":1580940856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X15301178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001]]},"references-count":96,"alternative-id":["S1198743X15301178"],"URL":"https:\/\/doi.org\/10.1046\/j.1469-0691.2001.00060.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2001]]}}}